AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05553444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Description: The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks.
Study NCT06345235 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in groups 1, 2, 3
Study NCT05226390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-SARS-2-ST
Description: In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
Study NCT05444803 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: femoral nerve block
Description: Patients will be performed a femoral nerve block using bupivacaine thirty minutes before the performing of spinal block.
Study NCT05444803 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peri-capsular nerve group block
Description: Patients will be performed a peri-capsular nerve group block using bupivacaine thirty minutes before the performing of spinal block.
Study NCT05485662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hydroxyapatite toothpaste
Description: 10% Hydroxyapatite toothpaste
Study NCT05485662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Fluoride Toothpaste
Description: 1450 parts per million sodium fluoride toothpaste
Study NCT06175364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Professionals in the Field of Orthotics Prosthetics
Description: Three data collection tools will be used as data collection methods for the research. These data collection tools; demographic information form, Health Sciences Evidence-Based Practice Survey and Information Literacy Self-Efficacy Scale.
Study NCT06307288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T4
Description: Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T4
Description: Verum T4 is a 17500AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Study NCT06307288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranilast
Description: The patient was treated with oral tranilast, 0.1g each time, three times a day, for 12 weeks.
Study NCT06428539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-reg cells
Description: laboratory test
Study NCT05017935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal angiogram and renal denervation (Paradise ultrasound Renal Denervation System)
Study NCT05545306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
Study NCT05545306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: -25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Description: -25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
Study NCT06441591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinpocetine
Description: Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel
Study NCT06441591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Therapy
Description: Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
Study NCT06441591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
Study NCT06441591 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch-filled capsules, matching those of the intervention
Study NCT04882254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion
Description: Additional 2h of normothermic machine perfusion of the donor kidney with a red cell based perfusate.
Study NCT05730920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: IV Methadone
Study NCT05730920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB, Exparel)
Description: LB and bupivacaine hydrochloride via erector spinae plane blocks
Study NCT05545306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: +150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein
Description: +150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
Study NCT06143202 — intervention group
Intervention type: DEVICE
Intervention: Freestyle Libre 3 Continuous Glucose Monitor
Description: Pediatric participants will wear a blinded Freestyle Libre 3 CGM. Data will not be available, and therefore the device will not be used to modify medical management.
Study NCT06212492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMBAs
Description: Early and systematic use of NMBAs
Study NCT06212492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone positioning
Description: Early and systematic use of prone positioning
Study NCT06212492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: Early and systematic use of prone positioning
Study NCT06562920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab and chemotherapy
Description: 3 cycles of adebrelimab combined with chemotherapy and concurrent SBRT, and undergo surgery within 4-6 weeks after treatment.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T5
Description: Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T5
Description: Verum T5 is a 17500AAIU/g white kidney bean extract. Daily dosage is 371 mg in 3 capsules
Study NCT04902066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Virtual Reality Therapy.
Description: Cognitive Behavioural Therapy augmented with Virtual Reality.
Study NCT04902066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive Behavioural Therapy
Description: Traditional Cognitive Behavioural Therapy for psychosis.
Study NCT04579120 — intervention group
Intervention type: DRUG
Intervention: F 18 AV-1451 (Flortaucipir)
Description: A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
Study NCT04293848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibroacoustic therapy
Description: listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
Study NCT04293848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Only music (no vibrations)
Description: listening to music, no vibrations
Study NCT06480110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Ebastine
Description: Ebastine is administered once daily.
Study NCT06480110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel every three weeks
Study NCT06434740 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy，SBRT
Description: The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.
Study NCT06434740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puterizumab
Description: Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
Study NCT05859620 — intervention group
Intervention type: OTHER
Intervention: Patient assessment and follow-up
Description: There is no study-specific intervention. The investigators will record data generated by clinical activity before, during and after implementation of the PMI-screening. Follow-up data and the final PMI event adjudication will be the only data generated specifically for this study.
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T6
Description: Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T6
Description: Verum T6 is a 34200AAIU/g white kidney bean extract. Daily dosage is 1000 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T7
Description: Verum T4 is a 34200AAIU/g white kidney bean extract. Daily dosage is 512 mg in 3 capsules
Study NCT06469580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NPLUS (neonatologist performed lung ultrasound)
Description: NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists.
Study NCT04879485 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood products
Description: Compare two different transfusion strategies against standard transfusion regimen
Study NCT06394219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional transperitoneal laparoscopic pyelolithotomy
Description: Performing anterior Pyelotomy.
Study NCT06394219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified transperitoneal laparoscopic pyelolithotomy
Description: Performing posterior pyelotomy
Study NCT04843111 — intervention group
Intervention type: BIOLOGICAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study NCT06436313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Sessions
Description: Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS.
Study NCT05450055 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intraperitoneal lidocaine analgesic or normal saline as control
Description: Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
Study NCT05450055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal lidocaine analgesic or normal saline as control
Description: Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
Study NCT05221125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychologically-Informed Physical Therapy (PIPT)
Description: The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
Study NCT05414123 — intervention group
Intervention type: DEVICE
Intervention: CNSide
Description: The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
Study NCT05315310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Exosuit
Description: A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
Study NCT03873207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PopSole™ offloading device
Description: Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
Study NCT03873207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: padded insole
Description: the control arm will be provided with standard padded insole to wear inside footwear
Study NCT06014424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Participants in this arm will receive CBD for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
Study NCT06014424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in this arm will receive placebo for 8 weeks during the first treatment period. They will then receive a two-week single-blind placebo washout before moving into the second 8-week treatment period, during which they will receive the opposite study treatment than the one given in the first treatment period.
Study NCT06562465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dietary and exercise management
Description: Dietary and exercise management: dietary management by providing tailored recipes, health education lectures, science competitions, etc；exercise management:develop weekly and monthly exercise plans for children of different ages, and have physical education teachers lead them in exercising.
Study NCT06562465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no dietary and exercise management
Description: NO dietary and exercise management:do not implement dietary and exercise management related to the experimental group
Study NCT05333107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 G
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
Study NCT05333107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 F
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study NCT05333107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0385-0434 B
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study NCT04914416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T8
Description: Verum T8 is a 34200AAIU/g white kidney bean extract. Daily dosage is 190 mg in 3 capsules.
Study NCT04985435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgotinib
Description: 200 mg tablet once daily or 100 mg once daily
Study NCT04985435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Tumor Necrosis Factor Alpha Drug (Product)
Description: Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
Study NCT05975125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C 500 MG Oral Tablet
Description: compare between Vitamin C with iron supplement and iron supplement alone in prevention of anemia in pregnancy.
Study NCT06652828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treadmill Walking (CTT)
Description: The CTT serves as a comparison to PBT. It involves standard treadmill walking without perturbations on the same treadmill. This intervention is conducted over the same defined period as PBT (3-6 weeks), with a matched frequency and exercise time compared to the PBT group for consistency. Participants are secured with safety harnesses while walking.
Study NCT06652828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation-Based Balance Training (PBT)
Description: Overall, 9 training sessions with different objectives and progression regarding perturbation directions, predictability, and intensity will be conducted within 3-6 weeks. During the initial sessions, familiarizing participants with the treadmill and establishing their individual walking pace will be focused. Pace can be individually adjusted in each training session. Participants are secured with safety harnesses while walking.
Study NCT04928404 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: tongue base suspension using barbed suture
Description: all patients will undergo multi-level surgeries .Therefor, Anterolateral advancement pharyngeoplasty (ALA) or Barbed Reposition Pharyngoplasty (BRP) will be applied to improve retro-palatal obstruction and tongue base suspension using barbed suture for retro-lingual obstruction.
Study NCT04985435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 50 patients will have a Free Choice between Filgotinib and anti TNF
Description: 50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.